4 unknown. 4 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 4 | Unknown 4 |
Follow Nasal Polyps: new trials by email Literature Review of Nasal Polyps trials Research Report on Nasal Polyps
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mepolizumab and In-office Nasal Polypectomy in Patients With Chronic Rhinosinusitis (CRS). A Three Arm Study. Mepolizumab, Polypeptomy - Rhinosinusitis Chronic, Polyp, Nasal | Phase 4 | Unknown | Instituto de Investigación Marqués de Valdecilla | 75 | 2023-09-01 | 2023-06-28 |
| Comparison of Immune Profiles in Chronic Rhinosinusitis Patients After Mepolizumab Treatment Mepolizumab, Placebo - Chronic Rhinosinusitis With Nasal Polyps, Asthma | Phase 4 | Unknown | St. Paul's Sinus Centre | 90 | 2023-07-01 | 2024-04-17 |
| The Role of Budesonide Intrapolyp Injection in CRSwNP Budesonide intrapolyp injection, Budesonide nasal wash, Prednisolone tablets - CRS, Polyp, Nasal | Phase 4 | Unknown | Kafrelsheikh University | 90 | 2022-08-01 | 2022-07-26 |
| Omalizumab Efficacy in Patients With Refractory Nasal Polyps Omalizumab, SNOT22 score - Nasal Polyps | Phase 4 | Unknown | Shiraz University of Medical Sciences | 2 | 2022-06-01 | 2022-06-06 |
Asthma (1)
Nose Diseases (4) · Otorhinolaryngologic Diseases (4) · Pathological Conditions, Anatomical (4) · Pathological Conditions, Signs and Symptoms (4) · Polyps (4) · Respiratory Tract Diseases (4) · Bronchial Diseases (1) · Hypersensitivity (1) · Hypersensitivity, Immediate (1) · Immune System Diseases (1) · Lung Diseases (1) · Lung Diseases, Obstructive (1) · Respiratory Hypersensitivity (1)
mepolizumab (2) · Budesonide (1) · Omalizumab (1) · Prednisolone (1)
Instituto de Investigación Marqués de Valdecilla (1) · Kafrelsheikh University (1) · Shiraz University of Medical Sciences (1) · St. Paul's Sinus Centre (1)
Canada (1) · Egypt (1) · Iran (1) · Spain (1)